Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients

Meropenem-vaborbactam is a broad-spectrum carbapenem–beta-lactamase inhibitor combination approved in the United States and Europe to treat patients with complicated urinary tract infections and in Europe for other serious bacterial infections, including hospital-acquired and ventilator-associated p...

Descripción completa

Detalles Bibliográficos
Autores principales: Trang, M., Griffith, D. C., Bhavnani, S. M., Loutit, J. S., Dudley, M. N., Ambrose, P. G., Rubino, C. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370236/
https://www.ncbi.nlm.nih.gov/pubmed/34097490
http://dx.doi.org/10.1128/AAC.02606-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370236/
https://www.ncbi.nlm.nih.gov/pubmed/34097490
http://dx.doi.org/10.1128/AAC.02606-20

Ejemplares similares